Tagged as: Glenmark Pharmaceuticals

Hetero and Glenmark Launch Adalimumab Biosimilars in India

Hetero announced this week the launch in India of its adalimumab biosimilar, marketed under the brand name Mabura.  Mabura is a biosimilar of AbbVie’s Humira and is indicated for the treatment of rheumatoid arthritis and other auto-immune disorders.  According to the company, Mabura is Hetero’s fourth biosimilar product. Glenmark also announced this…

Read More